Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug

New Multiple Sclerosis drug, backed by 40 years of research, could halt disease
June 22, 2017
Bowel cancer ‘breakthrough’ at Queen’s University 
June 22, 2017
Show all

Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug

Johnson & Johnson has acquired the rights to develop a new Crohn’s disease medication.

Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200. The deal gives J&J a stake in an oral interleukin-23 (IL-23) receptor antagonist in return for $50 million upfront and up to $940 million in milestones.

PTG-200, like other candidates developed by Protagonist, is an oral therapy, a delivery method that sets it apart from other Crohn’s drugs. J&J first expressed an interest in the technology by investing in the biotech. Having tracked the oral peptide specialist’s progress, J&J has now swooped to add the candidate to its pipeline.

The asset is due to enter the clinic this year. Protagonist will run and fund the trial with J&J taking over—and covering 80% of the costs—once it advances to phase 2. Beyond this, a series of major paydays await Protagonist. J&J will pay Protagonist $125 million if it moves the drug into phase 2b and a further $200 million if it sticks with the asset after getting a look at data from the trial. The rest of the cash is tied to regulatory and sales milestones.

Read full article: Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug | FierceBiotech

Read Full Article: Johnson & Johnson commits $990M to land Protagonist’s oral Crohn’s drug | FierceBiotech

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.